Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA ephedrine proposal

This article was originally published in The Tan Sheet

Executive Summary

Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) request staff briefing on dietary supplement issues, including FDA's proposed rule on ephedrine alkaloid-containing supplements, in Feb. 4 letter to agency. The letter says FDA's 1997 proposal to restrict serving sizes to 8 mg "appears to be based on 13 adverse event reports" and asks whether the number is "quantitatively sufficient, based on reasonable estimates of consumption for these products, to establish a causal relationship on which to base a serving limitation." The senators also ask whether the agency has "analyzed the trend in AERs to determine whether the number of scientifically reliable AERs" has changed since a 25 mg per serving, 100 mg per day standard was adopted by "major segments of the industry." They additionally seek updates on FDA regs on Good Manufacturing Practices for supplements and structure/function claims and request a briefing by Feb. 15

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts